An Extension Study to Evaluate Casimersen or Golodirsen in Patients With Duchenne Muscular Dystrophy



Sponsor:   Sarepta Therapeutics, Inc.


Sommario: 
      The main objective of this study is to evaluate the safety and tolerability of long-term
      treatment with casimersen or golodirsen in patients with Duchenne muscular dystrophy (DMD).
    




TIPOLOGIA STUDIO

 
Interventistico



FASE

 
Fase 3




TRATTAMENTO

  
    
  
  • Casimersen
  • Golodirsen
    • 






OBIETTIVO PRIMARIO


  
  • Misura: Number of Patients With Serious Adverse Events (SAEs)
  • Tempo: Up to 30 days after the last infusion of study drug (assessed up to 148 weeks)
  • Descrizione: 






CRITERI DI ELIGIBILITA'


    
             
  • 
        Criteri di inclusione e esclusione
        
    
        Inclusion Criteria:

          -  Completed a clinical trial evaluating casimersen or golodirsen, per protocol.

          -  Is between 7 and 23 years of age, inclusive, at enrollment.

        Other inclusion/exclusion criteria apply.
      
    
        
    • 
    




SESSO

  
Maschi




  


ETA' MINIMA



Età Minima: 7 Years

Età Massima: 23 Years






LUOGO


  
UOSD Centro Traslazionale di Miologia e Patologie Neurogenerative
Genova, 16147
Azienda Ospedaliero-Universitaria di Ferrara - Arcispedale Sant' Anna
Cona, 44124
Fondazione Policlinico Universitario A Gemelli
Milano, 20123